Every Form 4 that USANA Health Sciences Inc (USNA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow USNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full USNA filings page.
USANA Health Sciences chief operating officer Walter Noot reported routine equity compensation activity over three days in early February 2026. He exercised restricted stock units (RSUs) into common shares and had a portion of those shares withheld to cover tax obligations at a price of $21.34 per share.
On February 6, 7, and 8, 2026, RSU conversions delivered 3,375, 1,705, and 4,058 common shares, respectively, while 1,609, 813, and 1,738 shares were withheld for taxes. After these transactions, Noot directly held 4,978 shares of common stock and 41,179 RSUs.
USANA Health Sciences Chief Commercial Officer Brent Neidig reported multiple stock transactions over three days in February 2026 related to vested restricted stock units (RSUs). On February 6, 2026, 2,219 RSUs were converted into common stock, with 1,102 common shares disposed of at $21.34 per share, leaving 1,117 common shares directly held after that date.
On February 7, 2026, a further 1,401 RSUs were converted into common stock, with 696 common shares disposed of at $21.34 per share, resulting in 1,822 directly held common shares. On February 8, 2026, 3,690 RSUs were converted, with 1,753 common shares disposed of at $21.34 per share and 3,759 common shares directly held afterward.
Following these transactions, Neidig directly held 3,759 shares of common stock and 36,584 RSUs. Each RSU represents a contingent right to receive one share of USANA common stock, and the RSUs vest in 25% increments on the anniversaries of February 6, 2023, February 7, 2022, and February 8, 2024, as applicable.
USANA Health Sciences chief people officer Paul A. Jones reported several equity compensation transactions in early February 2026. On February 6, 7 and 8, 2026, restricted stock units converted into common stock in amounts of 2,174, 1,372 and 2,514 shares at an exercise price of $0 per share.
On each of those dates, portions of common stock were disposed of in transactions coded "F" in amounts of 754, 476 and 872 shares at a price of $21.34 per share. Following these transactions, Jones directly owned 9,127 shares of USANA common stock and 25,585 restricted stock units, each RSU representing a contingent right to receive one share as they vest on specified anniversary dates.
USANA Health Sciences Chief Financial Officer Doug G. Iie kking reported multiple equity transactions over February 6–8, 2026. On each date, restricted stock units were exercised for 3,532, 2,231, and 4,084 shares of common stock, respectively, at an exercise price of $0 per share.
Related dispositions of common stock at $21.34 per share totaled 2,567, 1,612, and 2,746 shares on the same dates. Following these transactions, the officer directly held 2,922 shares of common stock and 41,579 restricted stock units, each representing the right to receive one share of USNA common stock.
USANA Health Sciences’ chief legal officer, Joshua Foukas, reported multiple equity compensation transactions. On February 6–8, 2026, restricted stock units (RSUs) covering 3,111, 1,571, and 3,597 units were converted into the same number of USANA common shares at an exercise price of $0 per share.
Across the same dates, Foukas disposed of 1,483, 749, and 1,586 common shares at $21.34 per share. Following these transactions, he directly held 4,461 common shares and 36,608 RSUs. Each RSU represents a right to one share and vests 25% annually on specified February anniversaries.
USANA Health Sciences CEO and Executive Chairman Kevin Guest reported equity award activity over three days in February 2026. On February 6, 7, and 8, 2026, restricted stock units vested and were converted into 12,061, 6,601, and 4,425 shares of USANA common stock, respectively, at an exercise price of $0 per unit.
On each vesting date, a portion of the newly issued shares—5,345, 2,796, and 1,875 shares—was withheld at $21.34 per share to cover tax obligations, reflected with transaction code “F.” After these transactions, Guest directly beneficially owned 40,853 shares of common stock and 52,336 restricted stock units.
The footnotes state that each restricted stock unit represents a contingent right to receive one share of USANA common stock and that the units vest 25% annually on the specified February anniversaries.
USANA Health Sciences director Timothy E. Wood reported equity transactions involving restricted stock units and common stock of USNA. On January 22, 2026, 1,058 restricted stock units were converted into an equal number of shares of common stock at an exercise price of $0, increasing his directly held common shares to 10,085.
On the same date, he disposed of 265 shares of common stock at a price of $22.51 per share, leaving 9,820 common shares held directly after the reported transactions. Following the RSU conversion, he reported 1,057 restricted stock units beneficially owned. The filing notes that each restricted stock unit represents a contingent right to receive one share of USNA common stock, with these RSUs vesting 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Frederic J. Winssinger reported the vesting and conversion of 1,058 restricted stock units into an equal number of USANA common shares on January 22, 2026. These shares were acquired at a stated price of $0 per share, reflecting the nature of restricted stock units as equity awards rather than open‑market purchases.
After this transaction, Winssinger directly held 7,044 shares of USANA common stock and 1,057 restricted stock units. The footnotes explain that each restricted stock unit represents the right to receive one share of common stock, and that this RSU grant vests in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Nixon J. Scott reported an equity award transaction. On January 22, 2026, 1,058 restricted stock units (RSUs) were converted into 1,058 shares of USANA common stock at an exercise price of $0.00 per share, reflecting the nature of RSUs as stock-based compensation rather than a cash purchase.
After this transaction, Scott directly owned 8,756 shares of USANA common stock and 1,057 RSUs. The RSUs vest in four equal 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026, each representing the right to receive one share of USANA common stock when vested.
USANA Health Sciences director Peggie Pelosi reported equity transactions dated January 22, 2026. A block of 1,058 restricted stock units converted into 1,058 shares of common stock at an exercise price of $0, increasing her direct common share holdings. On the same date, she disposed of 669 shares of common stock at $22.51 per share, leaving 4,975 common shares directly owned. Following the conversion, she also held 1,057 restricted stock units, each representing a contingent right to receive one share of USANA common stock, with vesting in 25% increments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) director Gilbert A. Fuller reported an equity award vesting and share issuance. On January 22, 2026, 1,058 restricted stock units (RSUs) were converted into 1,058 shares of USANA common stock at an exercise price of $0, reported with transaction code "M." Following this transaction, Fuller directly owned 1,058 shares of common stock and 1,057 RSUs.
The RSUs vest in four equal installments of 25% each on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. Each RSU represents a contingent right to receive one share of USANA common stock, reflecting a standard director equity compensation structure.
USANA Health Sciences director Fleming John Turman reported the vesting and settlement of restricted stock units into common shares. On January 22, 2026, 1,058 restricted stock units were converted into 1,058 shares of USANA common stock at a price of $0 per share, reflecting the nature of RSUs as equity compensation rather than a market purchase.
After this transaction, Turman directly owned 5,623 shares of USANA common stock and 1,057 restricted stock units. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026, illustrating a staggered equity incentive structure tied to ongoing service.
USANA Health Sciences director Ding Xia reported stock transactions related to vesting equity awards. On January 22, 2026, 1,058 restricted stock units converted into the same number of USANA common shares at an exercise price of $0.00. These shares came from previously granted equity that vests in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
On the same day, 392 common shares were disposed of at $22.51 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes on the vesting. After these transactions, Ding Xia directly held 6,584 shares of USANA common stock and 1,057 restricted stock units as derivative securities.
USANA Health Sciences Inc. insider reports small stock sale. The company’s Chief Sales Officer filed a Form 4 disclosing the sale of 873 shares of USANA common stock on 12/10/2025. The shares were sold at a price of $21 per share, using transaction code “S,” which indicates an open market or private sale.
After this transaction, the officer beneficially owns 8,387 shares of USANA common stock in direct ownership. The filing is made by a single reporting person and does not report any derivative securities activity.
USANA Health Sciences Inc. (USNA) reported an insider stock transaction by its Chief Information Officer. On 12/10/2025, the officer sold 2,673 shares of common stock in an open market transaction at a price of $20.9506 per share, coded as a sale ("S"). After this transaction, the reporting person held 0 shares of USANA common stock in direct ownership. The filing covers only non-derivative common stock, with no derivative securities reported.
USANA Health Sciences (USNA) Form 4: A director reported an open-market sale of common stock. On 11/10/2025, the director sold 2,000 shares (transaction code S) at a price of $19.21 per share. Following this transaction, the director beneficially owns 5,986 shares, held directly.
USANA Health Sciences (USNA) director reported a sale of 1,057 shares of common stock (Code S) at $21.4799 on 11/03/2025. Following the transaction, the director beneficially owned 0 shares, held as direct ownership (D).
USANA Health Sciences (USNA) reported an insider transaction on a Form 4. A company director sold 1,750 shares of Common Stock on 10/31/2025 at a price of $19.79 per share (transaction code: S for open-market sale). After this trade, the insider directly beneficially owns 4,565 shares.
USANA Health Sciences (USNA) — director Form 4 activity. On 10/23/2025, 1,057 shares of common stock were acquired via the vesting/settlement of restricted stock units (code M). To cover taxes, 606 shares were withheld/disposed at $20.63 (code F). Following these transactions, the director directly owned 4,586 shares. The related RSU award had a $0 exercise price and continues to vest in scheduled 25% installments on specified dates.
USANA Health Sciences (USNA) reported an insider transaction by a director on 10/23/2025. The filing shows the conversion of restricted stock units into 1,057 shares of common stock (Transaction Code M) and a separate Code F disposition of 265 shares at $20.63 per share.
Following these transactions, the reporting person directly held 9,027 shares of common stock and 2,115 restricted stock units. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) reported an insider stock acquisition by a director. On 10/23/2025, the director acquired 1,057 shares of common stock through the settlement of restricted stock units, coded M (derivative conversion).
The shares were delivered at a stated price of $0. Following the transaction, the director beneficially owns 7,986 shares directly, with 2,115 RSUs remaining outstanding. Each RSU represents the right to receive one share of USNA common stock. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) disclosed a Form 4 showing a director acquired 1,057 shares of common stock on 10/23/2025 via transaction code M, reflecting the settlement of restricted stock units into shares.
Following the transaction, the director beneficially owned 7,698 common shares directly. The filing also shows 2,115 restricted stock units beneficially owned after the event, with vesting scheduled at 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The derivative security price is listed as $0, consistent with RSU settlement.
USANA Health Sciences (USNA) reported a director’s acquisition of 1,057 shares of common stock on 10/23/2025, coded “M” for settlement of restricted stock units.
After the transaction, the reporting person beneficially owns 1,057 shares directly and 2,115 restricted stock units. The RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) disclosed an insider transaction by a director on 10/23/2025. The filing reports the acquisition of 1,057 shares of common stock via the settlement of restricted stock units (Transaction Code M). Following the transaction, the reporting person directly owns 6,315 common shares and holds 2,115 restricted stock units.
The RSUs vest in four equal installments of 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The RSU settlement carried a stated price of $0 for the underlying common shares, consistent with equity award vesting mechanics.
USANA Health Sciences (USNA) disclosed insider activity dated 10/23/2025. A director acquired 1,057 shares of common stock through the conversion of restricted stock units (code M) and disposed of 476 shares (code F) at $20.63.
After the transactions, the director beneficially owned 5,918 common shares directly and held 2,115 restricted stock units. These RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.